Keiichiro Mori1,2, Hadi Mostafaei1,3, Noriyoshi Miura1,4, Pierre I Karakiewicz5, Stefano Luzzago5,6, Manuela Schmidinger7, Andreas Bruchbacher1,7, Benjamin Pradere1,8,9, Shin Egawa2, Shahrokh F Shariat10,11,12,13,14,15,16,17. 1. Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. 2. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. 3. Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan. 5. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada. 6. Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy. 7. Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 8. Department of Urology, University Hospital of Tours, Tours, France. 9. Université François Rabelais de Tours, PRES Centre Val de Loire, Tours, France. 10. Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduriwien.ac.at. 11. Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduriwien.ac.at. 12. Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduriwien.ac.at. 13. Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduriwien.ac.at. 14. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduriwien.ac.at. 15. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduriwien.ac.at. 16. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. shahrokh.shariat@meduriwien.ac.at. 17. European Association of Urology Research Foundation, Arnhem, Netherlands. shahrokh.shariat@meduriwien.ac.at.
Abstract
PURPOSE: Management of metastatic renal cell cancer (mRCC) has undergone a paradigm shift with immune-checkpoint inhibitors (ICI) in the first-line setting. However, direct comparative data are inadequate to inform treatment decisions. Therefore, we aimed to assess first-line therapy for mRCC and indirectly compare the efficacy and safety of currently available treatments. MATERIALS AND METHODS: Multiple databases were searched for articles published before June 2020. Studies that compared overall and/or progression-free survival (OS/PFS) and/or adverse events (AEs) in mRCC patients were considered eligible. RESULTS: Six studies matched our eligibility criteria. For OS, pembrolizumab plus axitinib [hazard ratio (HR) 0.85, 95% credible interval (CrI) 0.73-0.98] and nivolumab plus ipilimumab (HR 0.86, 95% CrI 0.75-0.99) were significantly more effective than sunitinib, and pembrolizumab plus axitinib was probably the best option based on analysis of the treatment ranking. For PFS, pembrolizumab plus axitinib (HR 0.86, 95% CrI 0.76-0.97) and avelumab plus axitinib (HR 0.85, 95% CrI 0.74-0.98) were statistically superior to sunitinib, and avelumab plus axitinib was likely to be the preferred option based on analysis of the treatment ranking, closely followed by pembrolizumab plus axitinib. Nivolumab plus ipilimumab had significantly lower rates of serious AEs than sunitinib. CONCLUSION: Pembrolizumab plus axitinib seemed to be the most efficacious first-line agents, while nivolumab plus ipilimumab had the most favorable efficacy-tolerability equilibrium. These findings may facilitate individualized treatment strategies and inform future direct comparative trials in an expanding treatment options without direct comparison between approved drugs.
PURPOSE: Management of metastatic renal cell cancer (mRCC) has undergone a paradigm shift with immune-checkpoint inhibitors (ICI) in the first-line setting. However, direct comparative data are inadequate to inform treatment decisions. Therefore, we aimed to assess first-line therapy for mRCC and indirectly compare the efficacy and safety of currently available treatments. MATERIALS AND METHODS: Multiple databases were searched for articles published before June 2020. Studies that compared overall and/or progression-free survival (OS/PFS) and/or adverse events (AEs) in mRCC patients were considered eligible. RESULTS: Six studies matched our eligibility criteria. For OS, pembrolizumab plus axitinib [hazard ratio (HR) 0.85, 95% credible interval (CrI) 0.73-0.98] and nivolumab plus ipilimumab (HR 0.86, 95% CrI 0.75-0.99) were significantly more effective than sunitinib, and pembrolizumab plus axitinib was probably the best option based on analysis of the treatment ranking. For PFS, pembrolizumab plus axitinib (HR 0.86, 95% CrI 0.76-0.97) and avelumab plus axitinib (HR 0.85, 95% CrI 0.74-0.98) were statistically superior to sunitinib, and avelumab plus axitinib was likely to be the preferred option based on analysis of the treatment ranking, closely followed by pembrolizumab plus axitinib. Nivolumab plus ipilimumab had significantly lower rates of serious AEs than sunitinib. CONCLUSION:Pembrolizumab plus axitinib seemed to be the most efficacious first-line agents, while nivolumab plus ipilimumab had the most favorable efficacy-tolerability equilibrium. These findings may facilitate individualized treatment strategies and inform future direct comparative trials in an expanding treatment options without direct comparison between approved drugs.
Authors: Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles Journal: N Engl J Med Date: 2019-02-16 Impact factor: 91.245
Authors: Brian I Rini; Thomas Powles; Michael B Atkins; Bernard Escudier; David F McDermott; Cristina Suarez; Sergio Bracarda; Walter M Stadler; Frede Donskov; Jae Lyun Lee; Robert Hawkins; Alain Ravaud; Boris Alekseev; Michael Staehler; Motohide Uemura; Ugo De Giorgi; Begoña Mellado; Camillo Porta; Bohuslav Melichar; Howard Gurney; Jens Bedke; Toni K Choueiri; Francis Parnis; Tarik Khaznadar; Alpa Thobhani; Shi Li; Elisabeth Piault-Louis; Gretchen Frantz; Mahrukh Huseni; Christina Schiff; Marjorie C Green; Robert J Motzer Journal: Lancet Date: 2019-05-09 Impact factor: 79.321
Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245
Authors: David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffery R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim A Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins Journal: J Clin Oncol Date: 2005-01-01 Impact factor: 44.544
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Eleonora A Braga; Marina V Fridman; Elena A Filippova; Vitaly I Loginov; Irina V Pronina; Alexey M Burdennyy; Alexander V Karpukhin; Alexey A Dmitriev; Sergey G Morozov Journal: Int J Mol Sci Date: 2021-10-17 Impact factor: 5.923
Authors: Robert J Motzer; Toni K Choueiri; David F McDermott; Thomas Powles; Yann-Alexandre Vano; Saurabh Gupta; Jin Yao; Celine Han; Ron Ammar; Simon Papillon-Cavanagh; Shruti S Saggi; M Brent McHenry; Petra Ross-Macdonald; Megan Wind-Rotolo Journal: J Immunother Cancer Date: 2022-03 Impact factor: 12.469